NCT04667650

Ocular Mysathenia Gravis Generalization

Use of Nomogram for Predictions of Ocular Mysathenia Gravis Generalization

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 151 (actual)
• Sponsor: Fondation Ophtalmologique Adolphe de Rothschild · Network
• Sex: All
• Age: —
• Healthy volunteers: Not accepted

Summary

Secondary ocular myasthenia gravis (OMG) generalization represents a pejorative evolution and no validated generalization prevention strategy exists. The aim of this observational study was to determine the percentage of patients with OMG generalization and identify factors predictive of that pejorative evolution. Data from patients with OMG registered in the Fondation Hospital A. de Rothschild database between January 1990 and January 2017 were collected. Among the 183 patients registered in this database, 151 patients with available informations were analyzed.

Conditions

• Ocular Myasthenia Gravis

Interventions

Type	Name	Description
OTHER	Use of nomogram for predictions of Ocular Mysathenia Gravis generalization	The outcome measure was time to Myasthenia gravis generalization. The explanatory variables were age at onset, sex, first-year anti-acetylcholinereceptor antibody positivity, repetiting nerve stimulation showing electromyogram decrement and steroid use. Kaplan-Meier survival estimations, descriptive and multivariate Cox model analyses were computed. A nomogram combining explanatory vraiables was used to establish a score to predict the probability of OMG generalization.

Timeline

• Start date: 2017-01-01
• Primary completion: 2019-01-01
• Completion: 2020-01-01
• First posted: 2020-12-16
• Last updated: 2020-12-16

Locations

1 site across 1 country: France